BR0208306A - Composições farmacêuticas - Google Patents

Composições farmacêuticas

Info

Publication number
BR0208306A
BR0208306A BR0208306-0A BR0208306A BR0208306A BR 0208306 A BR0208306 A BR 0208306A BR 0208306 A BR0208306 A BR 0208306A BR 0208306 A BR0208306 A BR 0208306A
Authority
BR
Brazil
Prior art keywords
water soluble
pharmaceutical compositions
surfactant
active ingredient
combination
Prior art date
Application number
BR0208306-0A
Other languages
English (en)
Inventor
Andreas Ebner
Bruno Galli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001117049 external-priority patent/DE10117049A1/de
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0208306A publication Critical patent/BR0208306A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"COMPOSIçõES FARMACêUTICAS". Composição sólida consistindo em (a) um tensoativo aniónico em combinação com um polímero básico solúvel em água, ou (b) um tensoativo catiónico em combinação com um polímero ácido solúvel em água, e (c) pelo menos um ingrediente farmaceuticamente ativo com pouca solubilidade em água e formas de dosagem sólidas ou líquidas, especialmente comprimidos, comprimidos revestidos, cápsulas ou supositórios ou soluções aquosas que incluem a composição sólida. O sistema tensoativo/polímero é solúvel em água e solubiliza o ingrediente ativo de modo que pode ser obtida boa biodisponibilidade com quantidades terapêuticas. Soluções aquosas são adequadas para tratamentos nasal, parenteral ou oftálmico.
BR0208306-0A 2001-03-26 2002-03-26 Composições farmacêuticas BR0208306A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10114869 2001-03-26
DE2001117049 DE10117049A1 (de) 2001-04-05 2001-04-05 Zusammensetzung
PCT/EP2002/003387 WO2002076432A2 (en) 2001-03-26 2002-03-26 Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer

Publications (1)

Publication Number Publication Date
BR0208306A true BR0208306A (pt) 2004-03-09

Family

ID=26008913

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208306-0A BR0208306A (pt) 2001-03-26 2002-03-26 Composições farmacêuticas

Country Status (15)

Country Link
US (5) US20040077232A1 (pt)
EP (1) EP1372611B1 (pt)
JP (1) JP4330343B2 (pt)
CN (1) CN100350911C (pt)
AT (1) ATE326216T1 (pt)
AU (1) AU2002304784A1 (pt)
BR (1) BR0208306A (pt)
CA (1) CA2439097C (pt)
CY (1) CY1106159T1 (pt)
DE (1) DE60211494T2 (pt)
DK (1) DK1372611T3 (pt)
ES (1) ES2261671T3 (pt)
HK (1) HK1061515A1 (pt)
PT (1) PT1372611E (pt)
WO (1) WO2002076432A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077883A2 (de) * 2002-03-15 2003-09-25 Kuyus Stiftung Zusammensetzung und verwendung derselben zur bildung eines schutzfilms auf nasenschleimhäuten
JO2897B1 (en) 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
PT2054040E (pt) * 2006-08-16 2011-06-30 Novartis Ag Método para produzir dispersões sólidas de compostos terapêuticos altamente cristalinos
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
JP6003653B2 (ja) * 2011-08-17 2016-10-05 東レ株式会社 医療デバイスおよびその製造方法
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
PE20171646A1 (es) * 2014-12-02 2017-11-13 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
KR20170084736A (ko) * 2016-01-12 2017-07-21 삼성디스플레이 주식회사 표시장치
EP3484520A4 (en) 2016-07-13 2020-07-29 Reform Biologics, LLC STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS
US11642199B2 (en) * 2018-09-24 2023-05-09 3M Innovative Properties Company Dental appliance with cosmetic therapeutic aqueous solution
CN113797162B (zh) * 2020-06-17 2023-05-05 成都瑞沐生物医药科技有限公司 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3754082A (en) * 1970-06-11 1973-08-21 Richardson Merrell Inc Process and composition for botfly larvae eliminination
CA1141663A (en) * 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
EP1004309A4 (en) * 1997-05-27 2001-01-17 Senju Pharma Co AQUEOUS PREPARATIONS CONTAINING ISRAPAFANT
TW546151B (en) * 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression

Also Published As

Publication number Publication date
ATE326216T1 (de) 2006-06-15
CA2439097A1 (en) 2002-10-03
CN1499959A (zh) 2004-05-26
US20040077232A1 (en) 2004-04-22
JP2004534739A (ja) 2004-11-18
US20160287707A1 (en) 2016-10-06
CY1106159T1 (el) 2011-06-08
CN100350911C (zh) 2007-11-28
AU2002304784A1 (en) 2002-10-08
US20140018346A1 (en) 2014-01-16
DK1372611T3 (da) 2006-09-18
WO2002076432A3 (en) 2002-12-12
EP1372611A2 (en) 2004-01-02
HK1061515A1 (en) 2004-09-24
US20080287417A1 (en) 2008-11-20
EP1372611B1 (en) 2006-05-17
US20140303145A1 (en) 2014-10-09
JP4330343B2 (ja) 2009-09-16
PT1372611E (pt) 2006-08-31
DE60211494D1 (de) 2006-06-22
CA2439097C (en) 2010-10-12
ES2261671T3 (es) 2006-11-16
DE60211494T2 (de) 2006-10-12
WO2002076432A2 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
BR0208306A (pt) Composições farmacêuticas
FI112778B (fi) Menetelmä vesipitoisen lääkekoostumuksen valmistamiseksi, jolla on palautuva kuumakovettuva geeliytymisominaisuus
FR2843302B1 (fr) Forme galenique pour la delivrance colique de principes actifs
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
BRPI0110914B8 (pt) 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
CA2382886A1 (en) Benzamide formulation with histone deacetylase inhibitor activity
PT1102579E (pt) Formulacoes de aerossol medicinais
NO20030533L (no) Vandige farmasöytiske preparater
CA2460865A1 (en) Quinoline derivatives as neuropeptide y antagonists
DE60019334D1 (de) Antivirale arznei
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
BR0008713A (pt) Processos para preparar formulações ecomposições farmacêuticas orais com ecb
BR9809571A (pt) Composição medicinal e processo para produzì-la
JP2005082512A (ja) イオン性の薬物の経皮吸収性を高めた外用剤
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
NO323466B1 (no) Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater
JP2003055258A (ja) 安定化された組成物
DK1009380T3 (da) Fremgangsmåde til fremstilling af farmaceutiske formuleringer
BRPI0113372B8 (pt) composição veterinária com veículo modificado e ceftiofur
PT986386E (pt) Uso de derivados heterociclicos aromaticos com azoto no tratamento topico de doencas dos tecidos epiteliais
JP2003055223A (ja) 安定化された組成物
SE9900177D0 (sv) Vårtmedel
JP2003055222A (ja) 安定化された組成物
JP2003055227A (ja) 安定化された組成物

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time